2. Search Result
Search Result
Results for "

CD73 inhibitor

" in MedChemExpress (MCE) Product Catalog:

56

Inhibitors & Agonists

7

Inhibitory Antibodies

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131967
    CD73-IN-4

    		CD73 Inflammation/Immunology Cancer
    CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology .
    CD73-IN-4
  • HY-145334
    CD73-IN-5

    		CD73 Cancer
    CD73-IN-5 is a potent and selective non-nucleotide small molecule inhibitor of CD73 (IC50 = 19 nM).
    CD73-IN-5
  • HY-175319
    CD73-IN-21

    		CD73 Cancer
    CD73-IN-21 (Compound 12f) is an Ecto-5′-nucleotidase (CD73) inhibitor with Kis of 20 and 302  nM for hCD73 and mCD73, respectively. CD73-IN-21 can be used for cancers like breast cancer research .
    CD73-IN-21
  • HY-162554
    CD73-IN-15

    		CD73 Inflammation/Immunology Cancer
    CD73-IN-15 (compound 12f) is a potent inhibitor of CD73, with the IC50 of 60 nM. CD73-IN-15 plays an important role in cancer research .
    CD73-IN-15
  • HY-144209
    CD73-IN-6

    		CD73 Cancer
    CD73-IN-6 is a CD73 inhibitor extracted from patent WO2022007677A1 compound 2. CD73-IN-6 can be used for the research of cancer .
    CD73-IN-6
  • HY-147594
    CD73-IN-13

    		CD73 Cancer
    CD73-IN-13 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-13 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437039A, compound 7) .
    CD73-IN-13
  • HY-162918
    CD73-IN-17

    		CD73 Cancer
    CD73-IN-17 (compound 19) is a CD73 inhibitor with IC50 of 0.1 μM for hCD73. CD73-IN-17 can be used in anti-cancer research .
    CD73-IN-17
  • HY-169189
    CD73-IN-18

    		CD73 Cancer
    CD73-IN-18 (compound 35j) is an orally available inhibitor of extracellular 5-nucleotidase (CD73). CD73-IN-18 can be used in anti-cancer research .
    CD73-IN-18
  • HY-147593
    CD73-IN-12

    		CD73 Cancer
    CD73-IN-12 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-12 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437038A, compound 9) . CD73-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CD73-IN-12
  • HY-170525
    CD73-IN-19

    		CD73 Inflammation/Immunology
    CD73-IN-19 (Compound 4ab) is a CD73 inhibitor (with a 44% inhibition rate of CD73 enzymatic activity at 100 μM). CD73-IN-19 (at 10 μM and 100 μM) can completely antagonize the blockade of T cell proliferation induced by TCR (T cell receptor) triggering (which is induced by CD73 activity), and it can also inhibit the hA2A receptor activity in HEK-293 cells (Ki is 3.31 μM). CD73-IN-19 holds promise for research in the field of immune diseases .
    CD73-IN-19
  • HY-137246
    CD73-IN-3

    		CD73 Cancer
    CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research .
    CD73-IN-3
  • HY-147592
    CD73-IN-11

    		CD73 Inflammation/Immunology Cancer
    CD73-IN-11 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-11 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 24) .
    CD73-IN-11
  • HY-147591
    CD73-IN-10

    		CD73 Inflammation/Immunology Cancer
    CD73-IN-10 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-10 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 4) .
    CD73-IN-10
  • HY-147589
    CD73-IN-8

    		CD73 Cancer
    CD73-IN-8 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-8 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 57) .
    CD73-IN-8
  • HY-147590
    CD73-IN-9

    		CD73 Inflammation/Immunology
    CD73-IN-9 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-9 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 2) .
    CD73-IN-9
  • HY-147588
    CD73-IN-7

    		CD73 Cancer
    CD73-IN-7 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-7 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 13) .
    CD73-IN-7
  • HY-131435
    CD73-IN-2

    		CD73 Cancer
    CD73-IN-2 is a potent CD73 inhibitor extracted from WO2020151707A1, example 1, has an IC50 of 0.09 nM .
    CD73-IN-2
  • HY-P990263
    Anti-Mouse CD73 Antibody (TY/23)

    		CD73 Infection Inflammation/Immunology Cancer
    Anti-Mouse CD73 Antibody (TY/23) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD73. Anti-Mouse CD73 Antibody (TY/23) can neutralize CD73. Anti-Mouse CD73 Antibody (TY/23) can be used for the researches of cancer, infection and immunology, such as B16F10 tumor and murine cytomegalovirus infection .
    Anti-Mouse CD73 Antibody (TY/23)
  • HY-103695
    CD73-IN-1

    		CD73 Cancer
    CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
    CD73-IN-1
  • HY-137682A
    GMPCP trisodium

    GpCp trisodium

    		 CD73 Cancer
    GMPCP (GpCp) trisodium (Compound 7 trisodium) is a guanosine derivative is a CD73 inhibitor, with Kis of 1110 nM (rat soluble CD73) and 410 nM (human soluble CD73) respectively. GMPCP (GpCp) trisodium can be used for research of cancer .
    GMPCP trisodium
  • HY-172527
    CD73-IN-20

    		CD73 Phosphodiesterase (PDE) Phosphatase Cancer
    CD73-IN-20 (Compound 5c) is an e5′NT (CD73) inhibitor (IC50: 0.37 μM). CD73-IN-20 also inhibits other ectonucleotidases, with IC50s of 1.12 μM (h-ENPP1), 1.37 μM (h-ENPP3), 1.66 μM (r-e5′NT), 1.48 μM (h-TNAP), respectively. CD73-IN-20 can be used for cancer research .
    CD73-IN-20
  • HY-172801
    PSB-24000

    		CD73 Cancer
    PSB-24000 (Compound 27) is a selective ecto-5'-nucleotidase (CD73) inhibitor with a Ki value of 563 nM against human CD73 (Ki= 481 nM at membrane-bound CD73 in triple-negative breast cancer cells). PSB-24000 interferes with CD73's recognition and action on the substrate AMP, and prevents the generation of immunosuppressive and cancer-promoting adenosine from AMP. PSB-24000 is promising for research of cancers .
    PSB-24000
  • HY-161774
    ST80

    		CD73 Cancer
    ST80 is an inhibitor for interaction of OTUD4 and CD73. ST80 decreases CD73 protein level, increases CD73 protein turnover, reduces immune evasion of tumor cells, and thus exhibits antitumor efficacy against immunosuppressive triple-negative breast cancer (TNBC) .
    ST80
  • HY-112502
    MethADP

    Adenosine 5'-(α,β-methylene)diphosphate

    		 CD73 Cancer
    MethADP is a specific CD73 inhibitor.
    MethADP
  • HY-112502A
    MethADP disodium

    Adenosine 5'-(α,β-methylene)diphosphate disodium

    		 CD73 Cancer
    MethADP disodium is a specific CD73 inhibitor.
    MethADP disodium
  • HY-152074
    CD73-IN-14

    		CD73 Cancer
    D73-IN-14 is a potent, selective and orally active CD73 inhibitor with an IC50 value of 0.17 nM. CD73-IN-14 increases the number of tumor-infiltrating CD8 + cells and shows anti-tumor activity . CD73-IN-14 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CD73-IN-14
  • HY-161677
    PD-L1/CD-73-IN-1

    		PD-1/PD-L1 CD73 Inflammation/Immunology Cancer
    PD-L1/CD-73-IN-1 (compound CC-5) is PD-L1/CD73 inhibitor with IC50 values of 6 nM and 0.773 μM to PD-L1 and CD73, respectively. PD-L1/CD-73-IN-1 inhibits tumor cell growth in vivo and in vitro .
    PD-L1/CD-73-IN-1
  • HY-137717A
    COPCP trisodium

    		CD73 Cancer
    COPCP trisodium (Compound 7a) is a potent and selective ecto-5'-nucleotidase CD73 inhibitor. COPCP trisodium blocks CD73-mediated adenosine production, reducing the inhibitory effect of adenosine on immune cells. COPCP trisodium is promising for research of cancers .
    COPCP trisodium
  • HY-162917
    CD73-IN-16

    		CD73 Cancer
    CD73-IN-16 (compound 18) is an inhibitor of hCD73 with IC50 values of 0.28 μM .
    CD73-IN-16
  • HY-171805
    PSB-0963

    		CD73 Cancer
    PSB-0963 is a selective and competitive ecto-5'-nucleotidase (eN/CD73) inhibitor with a Ki of 150 nM for rat ecto-5'-nucleotidase. PSB-0963 shows high selectivity over other ectonucleotidases (NTPDases 1-3) and P2Y receptors. PSB-0963 can be used for the study of cancer .
    PSB-0963
  • HY-173447
    8-BuS-AMP

    		NTPDase Cancer
    8-BuS-AMP is a CD39 and CD73 dual inhibitor. 8-BuS-AMP inhibits human CD39, mouse CD39 and human CD73 with Kis of 0.292, 2.19 and 1.19 μM, respectively .
    8-BuS-AMP
  • HY-176203
    XC-12

    		CD73 Cancer
    XC-12 is an orally active and potent small-molecule CD73 inhibitor (an immune checkpoint) with IC50 values of 12.36 nM and 1.29 nM against soluble and membrane-bound CD73 forms, respectively. XC-12 is promising for research of cancers .
    XC-12
  • HY-112502B
    MethADP sodium

    Adenosine 5'-(α,β-methylene)diphosphate sodium

    		 CD73 Cancer
    MethADP (sodium salt) (Adenosine 5'-(α,β-methylene)diphosphate (sodium)) is a specific CD73 inhibitor.
    MethADP sodium
  • HY-P99039
    Oleclumab
    1 Publications Verification

    MEDI9447

    		 CD73 Cancer
    Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
    Oleclumab
  • HY-P991330
    BMS-986179

    		CD73 Cancer
    BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .
    BMS-986179
  • HY-144072
    MRS4620

    		CD73 Inflammation/Immunology Cancer
    MRS4620 is a potent CD73 inhibitor, with a Ki of 0.436 nM. MRS4620 can be use for the research of cancer immunoresearch .
    MRS4620
  • HY-112502C
    MethADP triammonium

    Adenosine 5'-(α,β-methylene)diphosphate triammonium

    		 CD73 Cancer
    MethADP (Adenosine 5'-(α,β-methylene)diphosphate) triammonium is a CD73 inhibitor. MethADP can be used for the research of ATP-adenosine pathway .
    MethADP triammonium
  • HY-112502D
    MethADP trisodium

    Adenosine 5'-(α,β-methylene)diphosphate trisodium

    		 CD73 Cancer
    MethADP (Adenosine 5'-(α,β-methylene)diphosphate) trisodium is a CD73 inhibitor. MethADP trisodium can be used for the research of ATP-adenosine pathway .
    MethADP trisodium
  • HY-P99169
    Uliledlimab

    TJ004309

    		 CD73 Cancer
    Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
    Uliledlimab
  • HY-P991443
    IPH5301

    		CD73 Cancer
    IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    IPH5301
  • HY-100747
    PSB-12379
    3 Publications Verification

    		 CD73 Cancer
    PSB-12379, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human) .
    PSB-12379
  • HY-100747A
    PSB-12379 disodium

    		CD73 Cancer
    PSB-12379 disodium, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human) .
    PSB-12379 disodium
  • HY-136978
    OP-5244

    		CD73 Inflammation/Immunology Cancer
    OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research .
    OP-5244
  • HY-136978A
    OP-5244 sodium

    		CD73 Inflammation/Immunology Cancer
    OP-5244 sodium is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 sodium reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research .
    OP-5244 sodium
  • HY-P991634
    IBI-325

    		CD73 TNF Receptor Interleukin Related IFNAR Inflammation/Immunology Cancer
    IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research .
    IBI-325
  • HY-146759
    ZM514

    		CD73 Cancer
    ZM514 is a potent CD73 inhibitor with IC50s of 1.39 μM and 14.65 μM for hCD73 and mCD73, respectively. ZM514 has low cytotoxicity. ZM514 can be used for researching anticancer .
    ZM514
  • HY-125286
    AB-680
    Maximum Cited Publications
    16 Publications Verification

    		 CD73 Cancer
    AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity .
    AB-680
  • HY-P991612
    S095024

    Sym024

    		 CD73 Inflammation/Immunology Cancer
    S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
    S095024
  • HY-160696
    ORIC-533

    		CD73 Cancer
    ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment .
    ORIC-533
  • HY-125286A
    AB-680 ammonium

    		CD73 Cancer
    AB-680 ammonium is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity .
    AB-680 ammonium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: